Antibe Therapeutics Inc (ATE) EPS Estimated At $-0.01

November 24, 2017 - By Richard Conner

 Antibe Therapeutics Inc (ATE) EPS Estimated At $ 0.01

Investors wait Antibe Therapeutics Inc (CVE:ATE) to report on December, 5. its quarterly earnings Wall Street analysts expect $-0.01 EPS, $0.00 or 0.00 % from last year’s $-0.01 same quarter earnings. Antibe Therapeutics Inc’s Wall Street analysts see -50.00 % EPS growth, taking into account the $-0.02 EPS reproted in the previous quarter, It is down 0.00% since November 24, 2016 and is . It has underperformed by 16.70% the S&P500.

Antibe Therapeutics Inc. is a commercial-stage pharmaceutical company. The company has market cap of $14.67 million. The Firm is focused on pain, inflammation and regenerative medicine. It currently has negative earnings. The Company’s divisions include Antibe Therapeutics, and Citagenix, which is a marketer and distributor of regenerative medicines serving the dental and orthopedic market places.

More notable recent Antibe Therapeutics Inc (CVE:ATE) news were published by: Businesswire.com which released: “Antibe Therapeutics Announces Enrollment of First Subjects in Phase 2B GI …” on September 08, 2017, also Businesswire.com with their article: “Antibe Therapeutics Announces Successful Phase 2 Trial of ATB-346 in …” published on August 08, 2016, Businesswire.com published: “Antibe Therapeutics Enters into Regional Licensing Deal” on February 24, 2017. More interesting news about Antibe Therapeutics Inc (CVE:ATE) were released by: Businesswire.com and their article: “Antibe Therapeutics Reports Q1 2018 Interim Financial and Operating Results” published on August 29, 2017 as well as Businesswire.com‘s news article titled: “Antibe Therapeutics to Attend 2017 CPhI Worldwide Conference to Continue …” with publication date: October 20, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: